Total leg muscle function in hip OA patients is not well studied. We used a test-retest protocol to evaluate the reproducibility of single- and multi-joint peak muscle torque and rapid torque development in a group of 40–65 yr old hip patients. Both peak torque and torque development are outcome measures associated with functional performance during activities of daily living. Patients: Twenty patients (age 55.5±3.3, BMI 27.6±4.8) who underwent total hip arthroplasty participated in this study. Reliability: We used the intra-class correlation (ICC) and within subject coefficients of variation (CVws) to evaluate reliability. Agreement: Relative Bland-Altman 95% limits of agreements (LOA) and smallest detectable difference (SDD) were calculated and used for evaluation of measurement accuracy. Parameters: Maximal muscle strength (peak torque, Nm) and rate of torque development (Nm•sec-1) for affected (AF) and non-affected (NA) side were measured during unilateral knee extension-flexion (seated), hip extension-flexion, and hip adduction-abduction (standing), respectively. Contractile RTD100, 200, peak was derived as the average slope of the torque-time curve (torque/time) at 0–100, 0–200 and 0 peak relative to onset of contraction. Protocol: After 5 min level walking at self-selected and maximum speeds each muscle group was tested using 1–2 sub-maximal contraction efforts followed by 3 maximal contractions 4s duration. Statistics: The variance components were estimated using STATA12, with muscle function and occasion as independent variable and patients as random factor, using the restricted maximum likelihood method (=0.05).Introduction
Material and Methods
Background. Skeletal stem cells (SSCs) have been used for the treatment of osteonecrosis of the femoral head to prevent subsequent collapse. In isolation SSCs do not provide structural support but an innovative case series in Southampton, UK, has used SSCs in combination with impaction bone grafting (IBG) to improve both the biological and mechanical environment and to regenerate new bone at the necrotic site. Aims. Analysis of retrieved tissue-engineered bone as part of ongoing follow-up of this translational case series. Methods. With Proof-of-Concept established in vitro and in vivo, the use of a living bone composite of SSCs and allograft has been translated to four patients (five hips) for treatment of osteonecrosis of their femoral heads. Parallel in vitro culture of the implanted cell-graft construct was performed. Patient follow-up was by serial clinical and radiological examination. In one patient collapse occurred in both hips due to more advanced disease than was originally appreciated. This necessitated bilateral hip arthroplasty, but allowed retrieval of the femoral heads. These were analyzed for Type 1 Collagen production, bone morphology, bone density and
Introduction. In knee arthroplasty a ceramic component has several advantages: first, there is no ion release implying a risk for potential allergies. Second, the hardness of the material leads to a scratch resistance which ultimately reduces PE wear over time. In the past, ceramic components in knee applications were limited in the variety of design possibilities due to necessary thickness of the component resulting from the associated fracture risk of ceramics. By the development of an alumina matrix composite material with increased mechanical properties it is possible to develop ceramic knee components which have nearly the same design as a metal component and use the same implantation technique as well as the same instruments. This offers the surgeon the opportunity to choose intraoperatively between metal or ceramic knee components. Extensive in-vitro testing shows that ceramic knee components achieve superior mechanical test results. The reliability of the components is proven by two different burst tests and a fatigue test for both a femoral and a tibial ceramic knee component. Material and method. The mechanical proof-test was developed by subsequent steps of numerical load/stress analysis and design of an adequate mechanical test equipment. The procedure was organized as follows:. Oncologic: Analysis of relevant maximum in-vivo loading conditions. Analysis of the “boundary conditions”. Finite Element analysis: Identifying regions of highest stress concentration. Design analysis and accommodation if necessary. Development of an adequate mechanical test equipment which produces stresses comparable to the in-vivo conditions. Performing mechanical tests with ceramic femoral components. Validation of the test concept: comparison of test results and stress analysis. Assign “safety margin”,. Establish “proof test”. Results. Two independent load scenarios have been determined for each type of components as being in-vivo relevant. Hence, the developed proof-test consists of two subsequent load tests, the so-called regular test and the tension test for the femoral components, and the upper side test and the lower side test for the tibial components. In the regular test, the
Introduction. The combined incubation of a composite scaffold with bone marrow stromal cells in a perfusion bioreactor could make up a novel hybrid graft material with optimal properties for early fixation of implant to bone. The aim of this study was to create a bioreactor activated graft (BAG) material, which could induce early implant fixation similar to that of allograft. Two porous scaffold materials incubated with cells in a perfusion bioreactor were tested in this study. Methods and Materials. Two groups of 8 skeletally mature female sheep were anaesthetized before aspiration of bone marrow from the iliac crest. For both groups, mononuclear cells were isolated, and injected into a perfusion bioreactor (Millenium Biologix AG, Switzerland). Scaffold granules Ø∼900–1500 μm, ∼88% porosity) in group 1, consisted of hydroxyapatite (HA, 70%) with -tricalcium-phosphate (−TCP, 30%) (Danish Technological Institute, Denmark). The granules were coated with poly-lactic acid (PLA) 12%, in order to increase the
Bisphosphonates are widely used as first-line treatment for primary and secondary prevention of fragility fractures. Whilst they have proved effective in this role, there is growing concern over their long-term use, with much evidence linking bisphosphonate-related suppression of bone remodelling to an increased risk of atypical subtrochanteric fractures of the femur (AFFs). The objective of this article is to review this evidence, while presenting the current available strategies for the management of AFFs. We present an evaluation of current literature relating to the pathogenesis and treatment of AFFs in the context of bisphosphonate use.Objectives
Methods
We reviewed 59 bone graft substitutes marketed
by 17 companies currently available for implantation in the United Kingdom,
with the aim of assessing the peer-reviewed literature to facilitate
informed decision-making regarding their use in clinical practice.
After critical analysis of the literature, only 22 products (37%)
had any clinical data. Norian SRS (Synthes), Vitoss (Orthovita),
Cortoss (Orthovita) and Alpha-BSM (Etex) had Level I evidence. We question
the need for so many different products, especially with limited
published clinical evidence for their efficacy, and conclude that
there is a considerable need for further prospective randomised
trials to facilitate informed decision-making with regard to the
use of current and future bone graft substitutes in clinical practice. Cite this article:
